A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 06 Jan 2018 This study has been completed in Belgium (End date: 2017-10-02).
- 18 Dec 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology